MD4695C1 - Compus tiacumicinic şi regim de tratament asociat - Google Patents
Compus tiacumicinic şi regim de tratament asociatInfo
- Publication number
- MD4695C1 MD4695C1 MDA20160131A MD20160131A MD4695C1 MD 4695 C1 MD4695 C1 MD 4695C1 MD A20160131 A MDA20160131 A MD A20160131A MD 20160131 A MD20160131 A MD 20160131A MD 4695 C1 MD4695 C1 MD 4695C1
- Authority
- MD
- Moldova
- Prior art keywords
- tiacumicin compound
- days
- administering
- clostridium difficile
- tiacumicin
- Prior art date
Links
- 229930187202 Tiacumicin Natural products 0.000 title abstract 8
- 150000001875 compounds Chemical class 0.000 title abstract 8
- 238000011269 treatment regimen Methods 0.000 title 1
- 208000037384 Clostridium Infections Diseases 0.000 abstract 4
- 241000186000 Bifidobacterium Species 0.000 abstract 2
- 241000193163 Clostridioides difficile Species 0.000 abstract 2
- 206010012735 Diarrhoea Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Invenţia se referă la un compus tiacumicinic, un stereoizomer al acestuia, un polimorf al acestuia sau un solvat farmaceutic acceptabil al acestuia şi o compoziţie farmaceutică, ce conţine un compus tiacumicinic, un stereoizomer al acestuia, un polimorf al acestuia sau un solvat farmaceutic acceptabil al acestuia utilizate în tratamentul oral al infecţiilor provocate de Clostridium difficile (CDI) sau diareei sau bolii asociate cu Clostridium difficile (CDAD) la un pacient în conformitate cu un regim de dozare selectat din grupul ce constă din: i - administrarea a 200 mg de compus tiacumicinic BID timp de 5 zile, urmată de 5 zile de repaus, apoi 200 mg odată pe zi pentru următoarele 10 zile, şi ii - administrarea a 200 mg de compus tiacumicinic BID timp de 5 zile, urmată de administrarea unei singure doze de 200 mg peste o zi, timp de 20 de zile.De asemenea, se propune o metodă de restabilire a populaţiei de bifidobacterii din intestin la pacientul care suferă de infecţii provocate de Clostridium difficile (CDI) sau diareei sau bolii asociate cu Clostridium difficile (CDAD) şi care primeşte tratament oral cu un compus tiacumicinic, de la 50% până la 90% din populaţia de bifidobacterii din intestin cu administrarea compusului tiacumicinic, timp de 15...45 de zile de la începutul tratamentului, prin administrarea orală a compusului tiacumicinic la pacient în conformitate cu regimul de dozare, care este selectat din grupul menţionat mai sus.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14075031 | 2014-05-09 | ||
| PCT/EP2015/000965 WO2015169451A1 (en) | 2014-05-09 | 2015-05-11 | Treatment regimen tiacumicin compound |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| MD20160131A2 MD20160131A2 (ro) | 2017-05-31 |
| MD4695B1 MD4695B1 (ro) | 2020-05-31 |
| MD4695C1 true MD4695C1 (ro) | 2021-02-28 |
Family
ID=50771031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDA20160131A MD4695C1 (ro) | 2014-05-09 | 2015-05-11 | Compus tiacumicinic şi regim de tratament asociat |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US10137141B2 (ro) |
| EP (1) | EP3139932B1 (ro) |
| JP (1) | JP6579662B2 (ro) |
| KR (1) | KR20160149288A (ro) |
| AU (1) | AU2015258130B2 (ro) |
| CA (1) | CA2948400A1 (ro) |
| CY (1) | CY1120847T1 (ro) |
| DK (1) | DK3139932T3 (ro) |
| EA (1) | EA031756B1 (ro) |
| ES (1) | ES2694028T3 (ro) |
| GE (1) | GEP20186872B (ro) |
| HR (1) | HRP20181756T1 (ro) |
| IL (1) | IL248782B (ro) |
| LT (1) | LT3139932T (ro) |
| MA (1) | MA39952B1 (ro) |
| MD (1) | MD4695C1 (ro) |
| PL (1) | PL3139932T3 (ro) |
| PT (1) | PT3139932T (ro) |
| RS (1) | RS57994B1 (ro) |
| SI (1) | SI3139932T1 (ro) |
| TR (1) | TR201815891T4 (ro) |
| UA (1) | UA122203C2 (ro) |
| WO (1) | WO2015169451A1 (ro) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3316892B1 (en) * | 2015-07-03 | 2023-07-19 | Tillotts Pharma AG | Novel dosage regimen of tiacumicin compound |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4918174A (en) | 1986-09-26 | 1990-04-17 | Abbott Laboratories | Tiacumicin compounds |
| US5583115A (en) | 1995-05-09 | 1996-12-10 | Abbott Laboratories | Dialkyltiacumicin compounds |
| US5767096A (en) | 1996-07-12 | 1998-06-16 | Abbott Laboratories | Bromotiacumicin compounds |
| ES2527052T3 (es) | 2002-07-29 | 2015-01-20 | Optimer Pharmaceuticals, Inc. | Producción de tiacumicina |
| ES2713954T3 (es) * | 2004-05-14 | 2019-05-24 | Merck Sharp & Dohme | Tratamiento de enfermedades asociadas al uso de antibióticos |
| MX2007009196A (es) | 2005-01-31 | 2009-02-25 | Optimer Pharmaceuticals Inc | Compuestos macrocilicos de 18 miembros y analogos de los mismos. |
| US7378508B2 (en) | 2007-01-22 | 2008-05-27 | Optimer Pharmaceuticals, Inc. | Polymorphic crystalline forms of tiacumicin B |
| US20080176927A1 (en) * | 2007-01-19 | 2008-07-24 | Optimer Pharmaceuticals, Inc. | Compositions of stable tiacumicins |
| CN102030791B (zh) | 2010-10-28 | 2013-01-23 | 中国科学院南海海洋研究所 | 四种台勾霉素类化合物及其制备方法和在制备抗菌药物中的应用 |
| CN102115757B (zh) | 2010-12-14 | 2015-10-28 | 中国科学院南海海洋研究所 | 台勾霉素的生物合成基因簇及其应用 |
| US20150157653A1 (en) * | 2012-03-16 | 2015-06-11 | Optimer Pharmaceuticals, Inc. | Prevention of Clostridium Difficile Infection in High Risk Patients |
| JO3464B1 (ar) * | 2013-01-15 | 2020-07-05 | Astellas Pharma Europe Ltd | التركيبات الخاصة بمركبات التياكوميسين |
-
2015
- 2015-05-11 DK DK15731245.5T patent/DK3139932T3/en active
- 2015-05-11 RS RS20181271A patent/RS57994B1/sr unknown
- 2015-05-11 GE GEAP201514327A patent/GEP20186872B/en unknown
- 2015-05-11 PL PL15731245T patent/PL3139932T3/pl unknown
- 2015-05-11 CA CA2948400A patent/CA2948400A1/en not_active Abandoned
- 2015-05-11 SI SI201530443T patent/SI3139932T1/sl unknown
- 2015-05-11 KR KR1020167034087A patent/KR20160149288A/ko not_active Application Discontinuation
- 2015-05-11 EA EA201692107A patent/EA031756B1/ru unknown
- 2015-05-11 UA UAA201610790A patent/UA122203C2/uk unknown
- 2015-05-11 AU AU2015258130A patent/AU2015258130B2/en not_active Ceased
- 2015-05-11 WO PCT/EP2015/000965 patent/WO2015169451A1/en active Application Filing
- 2015-05-11 TR TR2018/15891T patent/TR201815891T4/tr unknown
- 2015-05-11 ES ES15731245.5T patent/ES2694028T3/es active Active
- 2015-05-11 JP JP2016567190A patent/JP6579662B2/ja active Active
- 2015-05-11 PT PT15731245T patent/PT3139932T/pt unknown
- 2015-05-11 EP EP15731245.5A patent/EP3139932B1/en active Active
- 2015-05-11 MA MA39952A patent/MA39952B1/fr unknown
- 2015-05-11 LT LTEP15731245.5T patent/LT3139932T/lt unknown
- 2015-05-11 MD MDA20160131A patent/MD4695C1/ro active IP Right Grant
- 2015-05-11 US US15/309,992 patent/US10137141B2/en not_active Expired - Fee Related
-
2016
- 2016-11-06 IL IL248782A patent/IL248782B/en active IP Right Grant
-
2018
- 2018-10-24 HR HRP20181756TT patent/HRP20181756T1/hr unknown
- 2018-10-30 CY CY181101119T patent/CY1120847T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3139932A1 (en) | 2017-03-15 |
| DK3139932T3 (en) | 2018-11-12 |
| MD4695B1 (ro) | 2020-05-31 |
| UA122203C2 (uk) | 2020-10-12 |
| CY1120847T1 (el) | 2019-12-11 |
| ES2694028T3 (es) | 2018-12-17 |
| CA2948400A1 (en) | 2015-11-12 |
| US20170143750A1 (en) | 2017-05-25 |
| US10137141B2 (en) | 2018-11-27 |
| RS57994B1 (sr) | 2019-01-31 |
| MA39952B1 (fr) | 2018-12-31 |
| AU2015258130A1 (en) | 2016-12-15 |
| AU2015258130B2 (en) | 2019-10-31 |
| LT3139932T (lt) | 2018-11-12 |
| MA39952A (fr) | 2017-03-15 |
| WO2015169451A1 (en) | 2015-11-12 |
| EA201692107A1 (ru) | 2017-04-28 |
| KR20160149288A (ko) | 2016-12-27 |
| JP2017514880A (ja) | 2017-06-08 |
| JP6579662B2 (ja) | 2019-09-25 |
| TR201815891T4 (tr) | 2018-11-21 |
| EA031756B1 (ru) | 2019-02-28 |
| MD20160131A2 (ro) | 2017-05-31 |
| IL248782A0 (en) | 2017-01-31 |
| IL248782B (en) | 2020-08-31 |
| PT3139932T (pt) | 2018-11-14 |
| PL3139932T3 (pl) | 2019-02-28 |
| HRP20181756T1 (hr) | 2018-12-28 |
| GEP20186872B (en) | 2018-06-25 |
| EP3139932B1 (en) | 2018-08-01 |
| SI3139932T1 (sl) | 2018-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
| BR112018005454A2 (pt) | administração de potencializadores de cftr deuterados | |
| MX2020003381A (es) | Composicion para la prevencion o el tratamiento de enfermedades relacionadas con el factor de necrosis tumoral (tnf), que contiene un nuevo derivado como ingrediente activo, y metodo para inhibir la actividad del factor de necrosis tumoral (tnf) mediante el uso de la misma. | |
| PE20190338A1 (es) | Metodos de tratamiento de trastornos del desarrollo con gaboxadol | |
| JP2017525713A5 (ro) | ||
| NZ625592A (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| JP2010535767A5 (ro) | ||
| EA202191079A1 (ru) | Способы лечения синдрома ретта с применением фенфлурамина | |
| MX2022015629A (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
| WO2016168553A8 (en) | Deuterated obeticholic acid | |
| HRP20192189T1 (hr) | Doziranja i terapijske primjene l-4-klorokinurenina | |
| PH12020551911A1 (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
| MX2024007642A (es) | Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades. | |
| PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
| RU2018146504A (ru) | Лечение внутрипеченочных холестатических заболеваний | |
| RU2017127509A (ru) | Композиции и способы для улучшенного мышечного метаболизма | |
| JP2016505050A5 (ro) | ||
| MD4695C1 (ro) | Compus tiacumicinic şi regim de tratament asociat | |
| MX2023002649A (es) | Nueva formulacion de acido gamma-aminobutirico. | |
| WO2016130518A3 (en) | Methods and compositions for treating muscle disease and disorders | |
| EA202090416A1 (ru) | Способы лечения симптомов гастропареза с использованием велусетрага | |
| AU2018333952A1 (en) | Methods and compositions to inhibit symptoms associated with opioid withdrawal | |
| TW201613600A (en) | Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically | |
| EA201992690A1 (ru) | Применение вибегрона для лечения гиперактивного мочевого пузыря |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG4A | Patent for invention issued | ||
| PD4A | Change of proprietorship (patent for invention) |
Owner name: TILLOTTS PHARMA AG, CH Free format text: PREVIOUS PROPRIETOR: ASTELLAS PHARMA EUROPE LTD, GB STR. 2000 HILLSWOOD DRIVE CHERTSEY, SURREY KT16 0RS, REGATUL UNIT, MAREA BRITANIE |